What The Article Says: This Viewpoint proposes ways to maximize vaccine efficacy and allocation given the rise of coronavirus variants and authorization of a Johnson & Johnson vaccine, including reserving the latter for younger healthier populations, boosting it with a single-dose messenger RNA (mRNA) vaccination and single mRNA immunization of people with prior documented SARS-CoV-2 infection.
Authors: John P. Moore, Ph.D., of Weill Cornell Medicine in New York, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https:/
Editor's Note: The article includes an Editor's Note. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Media advisory: The full article is linked to this news release. A livestream with the author also is scheduled for Thursday at 3:50 P.M. (ET) and will be available here: http://ja.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https:/